title: p53 overexpression and downregulation of inter-alpha-inhibitor are associated with hyaluronidase enhancement of TNF cytotoxicity in L929 fibroblasts.
abstract: Degradation of extracellular matrix by hyaluronidase increases murine L929 cell sensitivity to tumor necrosis factor (TNF) cytotoxicity. Seeding and culturing L929 cells onto the matrix of serum fetuin and the hyaluronate-binding inter-alpha-inhibitor resulted in inhibition of hyaluronidase-enhanced TNF killing, suggesting that the release of these proteins from hyaluronidase-degraded matrix confers cellular TNF susceptibility. Metabolic labeling studies showed that hyaluronidase mediated de novo protein synthesis and down regulated several proteins in L929 cells. Specifically, hyaluronidase upregulated p53 protein expression (>200%) but down regulated a p85 inter-alpha-inhibitor-like protein (>90%) in L929 cells, whereas it had no effect on the protein levels of ICH-1, Bcl-xL, Bcl-2, Fas ligand, CAS (cellular apoptosis susceptible protein), TIAR (an RNA-binding protein) and alpha-tubulin. Conceivably, hyaluronidase enhancement of TNF sensitivity in L929 cells is p53-dependent and the matrix inter-alpha-inhibitor contributes a protective role against TNF cytotoxicity.
authors.affiliation: Guthrie Research Institute, Laboratory of Molecular Immunology, Guthrie Medical Center, Sayre, PA 18840, USA. nschang@inet.guthrie.org
authors.forename: N S
authors.initials: NS
authors.lastname: Chang
authors.forename: G
authors.initials: G
authors.lastname: Carey
authors.forename: N
authors.initials: N
authors.lastname: Pratt
authors.forename: E
authors.initials: E
authors.lastname: Chu
authors.forename: M
authors.initials: M
authors.lastname: Ou
mesh_terms: D000510:Alpha-Globulins / Q000378:metabolism*; D000818:Animals; D016227:Benzoquinones; D002470:Cell Survival / Q000187:drug effects; D015536:Down-Regulation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D016158:Genes, p53; D006821:Hyaluronoglucosaminidase / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D047029:Lactams, Macrocyclic; D051379:Mice; D009363:Neoplasm Proteins / Q000096:biosynthesis; D011809:Quinones / Q000494:pharmacology; D019311:Staurosporine / Q000494:pharmacology; D014361:Trypsin Inhibitors / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*; D000509:alpha-Fetoproteins / Q000502:physiology
chemical_list: D000510:Alpha-Globulins; D016227:Benzoquinones; D004791:Enzyme Inhibitors; D047029:Lactams, Macrocyclic; D009363:Neoplasm Proteins; D011809:Quinones; D014361:Trypsin Inhibitors; D014409:Tumor Necrosis Factor-alpha; D000509:alpha-Fetoproteins; C011877:inter-alpha-inhibitor; D006821:Hyaluronoglucosaminidase; D019311:Staurosporine; C001277:geldanamycin